Carmot Therapeutics
2023
$250M
Why
Moderna acquired Carmot Therapeutics for $250 million to access CRISPR-based gene editing technology and RNA-targeted small molecule capabilities, expanding the company's platform beyond mRNA into gene editing and small molecule therapeutics. The acquisition was evaluated against alternative uses of capital and strategic priorities, with the board concluding that the technology provided competitive advantages.
Impact
The acquisition added CRISPR expertise and a pipeline of preclinical programs targeting genetic diseases, complementing Moderna's mRNA platform with permanent genetic modification capabilities. The integration required organizational adjustments and resource allocation decisions that shaped Moderna's platform capabilities.
Outcome
The Carmot technology has been integrated into Moderna's rare disease research organization, with programs advancing toward clinical development. The acquisition continues to contribute to Moderna's research and development efforts as part of the company's broader platform strategy.